Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial-Reference-Cited by-同舟云学术

Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

Published:2017-07 Issue:7 Volume:4 Page:e284-e294
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Aberg Judith A,Sponseller Craig A,Ward Douglas J,Kryzhanovski Vladimir A,Campbell Stuart E,Thompson Melanie A

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference31 articles.

1. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population;Rodger;AIDS,2013

2. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration;Lewden;Int J Epidemiol,2012

3. HIV infection: epidemiology, pathogenesis, treatment, and prevention;Maartens;Lancet,2014

4. Trends in cardiovascular disease mortality among persons with HIV in New York City, 2001–2012;Hanna;Clin Infect Dis,2016

5. HIV infection and the risk of acute myocardial infarction;Freiberg;JAMA Intern Med,2013

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma endocannabinoidome and fecal microbiota interplay in people with HIV and subclinical coronary artery disease: Results from the Canadian HIV and Aging Cohort Study;iScience;2024-08

2. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial;The Lancet Regional Health - Western Pacific;2024-08

3. Inflammatory and Immune Mechanisms for Atherosclerotic Cardiovascular Disease in HIV;International Journal of Molecular Sciences;2024-07-01

4. Primary Prevention of Cardiovascular Disease for People Living with Human Immunodeficiency Virus;Nursing Clinics of North America;2024-06

5. Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease;Circulation Research;2024-05-24